ArticleMedical mycology2026
Tinea corporis and tinea cruris incidence, risk factors, and treatments in a cohort of 6.8 million patients with Medicaid, United States.
Article in Medical mycology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic challenges and the evolving landscape of tinea infections.AME case reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tinea corporis and tinea cruris are common dermatophyte infections of increasing public health concern, yet national US data are limited. We estimated incidence, risk factors, and diagnostic and treatment practices among a large Medicaid-insured outpatient cohort. Among ∼6 800 000 enrollees, 54 108 were diagnosed with tinea corporis (79.1/10 000 person-years) and 8386 with tinea cruris (12.2/10 000 person-years). Tinea corporis primarily affected young children and Black patients, while tinea cruris was prevalent among middle-aged men. Overall, <10% received diagnostic testing, and 7%-10% were treated with combination antifungal-corticosteroid products, highlighting the opportunities to increase testing and promote judicious antifungal use amid emerging resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.